Treatment of bullous pemphigoid

Journal of Dermatology

Volumn 30, Issue 2, 2003, Pages 83-90

  Fontaine, Juliette ^a   Joly, Pascal ^b   Roujeau, Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Bullous pemphigoid; Clobetasol propionate; Corticosteroids

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISOLONE; PREDNISONE; TETRACYCLINE;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FOLLOW UP; HEART FAILURE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MORTALITY; MUTAGENICITY; NEPHROTOXICITY; OPEN STUDY; PEMPHIGOID; PLASMAPHERESIS; PNEUMONIA; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SKIN ATROPHY; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0345700259     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2003.tb00353.x     Document Type: Review

References (62)

1. Korman NJ: Bullous pemphigoid: The latest in diagnosis, prognosis and therapy, Arch Dermatol, 134: 1137-1141, 1998.
2. Nousari HC, Anhalt GJ: Pemphigus and bullous pemphigoid, Lancet, 354: 667-672, 1999.
3. Yancey KB, Egan CA: Pemphigoid: Clinical, histologic, immunopathologic, and therapeutic considerations, JAMA, 284: 350-356, 2000.
4. Bernard P, Vaillant L, Labeille B, et al: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions, Arch Dermatol, 131: 48-52, 1995.
5. Zillikens D, Wever S, Roth A, Hashimoto T, Brocker EB: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany, Arch Dermatol, 131: 957-958, 1995.
6. Courville P, Kupfer I, Gilbert D, Thomine E, Metayer J, Joly P: Evaluation of histological criteria for bullous pemphigoid. Correlation with antigens recognized by immunoblotting of antiepidermal autoantibodies, Ann Pathol, 20: 564-569, 2000.
7. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH: Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita, J Am Acad Dermatol, 22: 664-670, 1990.
8. Joly P, Gilbert D, Thomine E, et al: Relationship between the in vivo localization and the immunoblotting pattern of anti-basement membrane zone antibodies in patients with bullous pemphigoid, Arch Dermatol, 133: 719-724, 1997.
9. Stanley JR, Tanaka T, Mueller S, Klaus-Kovtun V, Roop D: Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies, J Clin Invest, 82: 1864-1870, 1988.
10. Diaz LA, Ratrie H, Saunders WS, et al: Isolation of a human cDNA corresponding to the 180 kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome, J Clin Invest, 86: 1088-1094, 1990.
11. Tanaka T, Parry DA, Klaus-Kovtun V, Steinert PM, Stanley JR: Comparison of molecularly cloned bullous pemphigoid antigen to desmoplakin I confirms that they define a new family of cell adhesion junction plaque proteins, J Biol Chem, 266: 1255-1259, 1991.
12. Giudice GJ, Emery DJ, Diaz LA: Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP 180, J Invest Dermatol, 99: 243-250, 1992.
13. Liu Z, Diaz LA, Troy JL, et al: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen BP180, J Clin Invest, 92: 2480-2488, 1993.
14. Bernard P, Bedane C, Bonnetblanc JM: Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: A cohort analysis of 94 elderly patients, Br J Dermatol, 136: 694-698, 1997.
15. Schmidt E, Obe K, Brocker EB, Zillikens D: Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid, Arch Dermatol, 136: 174-178, 2000.
16. Zillikens D: BP180 as the common autoantigen in blistering disseases with different clinical phenotypes, Keio J Med, 51: 21-28, 2002.
17. Vaillant L, Bernard P, Joly P, et al: Evaluation of clinical criteria for diagnosis of bullous pemphigoid, Arch Dermatol 134: 1075-1080, 1998.
18. Roujeau JC, Guillaume JC, Morel P, et al: Plasma exchange in bullous pemphigoid, Lancet, 2: 486-488, 1984.
19. Dreno B, Sassolas B, Lacour JP, et al: Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: A comparative multicenter study, Ann Dermatol Venereol, 120: 518- 521, 1993.
20. Morel P, Guillaume JC: Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/ kg/day versus 1.25 mg/kg/day, a multicenter randomized study, Ann Dermatol Venereol, 111: 925-928, 1984.
21. Guillaume JC, Vaillant L, Bernard P, et al: Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid, Arch Dermatol, 129: 49-53, 1993.
22. Lebrun-Vignes B, Roujeau JC, Bernard P, et al: Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid, Arch Dermatol, 135: 89-90, 1999.
23. Savin JA: The events leading to the death of patients with pemphigus and pemphigoid, Br J Dermatol, 101: 521-534, 1979.
24. Venning VA, Wojnarowska F: Lack of predictive factors for the clinical course of bullous pemphigoid, J Am Acad Dermatol, 26: 585-589, 1992.
25. Roujeau JC, Loc C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P: High risk of death in elderly patients with extensive bullous pemphigoid, Arch Dermatol, 134: 465-469, 1998.
26. Rzany B, Partscht K, Jung M, et al: Risk factors for lethal outcome in patients with bullous pemphigoid: Low serum albumin level, high dosage of glucocorticoids, and old age, Arch Dermatol, 138: 903-908, 2002.
27. Joly P, Roujeau JC, Benichou J, et al: A comparison of oral topical corticosteroids in patients with bullous pemphigoid, N Engl J Med, 346: 321-327, 2002.
28. Greaves MW, Burton JL, Marks J, Dawber RP: Azathioprine in the treatment of bullous pemphigoid, Br Med J, 1: 144-145, 1971.
29. Krain LS, Landau JW, Newcomer VD: Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid, Arch Dermatol, 106: 657-661, 1972.
30. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A: Effects of cyclosporin on bullous pemphigoid and pemphigus, Lancet, 1: 334-335, 1985.
31. Milligan A, Hutchinson PE: The use of chlorambucil in the treatment of bullous pemphigoid, J Am Acad Dermatol, 22: 796-801, 1990.
32. Paul MA, Jorizzo JL, Fleischer AB, White WL: Low-dose methotrexate treatment in elderly patients with bullous pemphigoid, J Am Acad Dermatol, 31: 620-625, 1994.
33. Heilborn JD, Stahle-Backdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E: Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid, J Am Acad Dermatol, 40: 741-749, 1999.
34. Itoh T, Hosokawa H, Shirai Y, Horio T: Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide, Br J Dermatol, 134: 931-933, 1996.
35. Bohm M, Beissert S, Schwarz T, Metze D, Luger T: Bullous pemphigoid treated with mycophenolate mofetil, Lancet, 349: 541, 1997.
36. Grundmann-Kollmann M, Korting HC, Behrens S, et al: Mycophenolate mofetil: A new therapeutic option in the treatment of blistering autoimmune disease, J Am Acad Dermatol, 40: 957-960, 1999.
37. Burton JL, Harman RR, Peachey RD, Warin RP, Azathioprine plus prednisone in the treatment of pemphigoid, Br Med J, 2: 1190-1191, 1978.
38. Ioannides D, Chrysomallis F, Bystryn JC: Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus, Arch Dermatol, 136: 868-872, 2000.
39. Egan CA, Meadows KP, Zone JJ: Plasmapheresis as a steroid saving procedure in bullous pemphigoid, Int J Dermatol, 39: 230-235, 2000.
40. Wollina U, Lange D, Looks A: Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases, Dermatology, 198: 140-144, 1999.
41. Godard W, Roujeau JC, Guillot B, Andre C, Rifle G: Bullous pemphigoid and intravenous gamma-globulin, Ann Intern Med, 103: 964-965, 1985.
42. Engineer L, Ahmed AR: Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: Analysis of current data, J Am Acad Dermatol, 44: 1-6, 2001.
43. Ahmed AR: Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment, J Am Acad Dermatol, 45: 825-835, 2001.
44. Bouscarat F, Chosidow O, Picard-Dahan C, et al: Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases, J Am Acad Dermatol, 34: 683-684, 1996.
45. Berk NA, Lorincz AL: The treatment of bullous pemphigoid with tetracycline and niacinamide, Arch Dermatol, 122: 670-674, 1986.
46. Thornfeldt CR, Menkes AW: Bullous pemphigoid controlled by tetracycline, J Am Acad Dermatol, 16: 305-310, 1987.
47. Thomas I, Khorenian S, Arbesfeld DM: Treatment of generalized bullous pemphigoid with oral tetracycline, J Am Acad Dermatol, 28: 74-77, 1993.
48. Kolbach DN, Remme JJ, Bos WH, et al: Bullous pemphigoid successfully controlled by tetracycline and nicotinamide, Br J Dermatol, 133: 88-90, 1995.
49. Pereyo NG, Davis LS: Generalized bullous pemphigoid controlled by tetracycline therapy alone, J Am Acad Dermatol, 32: 138-139, 1995.
50. Hornschuch B, Hamm H, Wever S, et al: Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol, J Am Acad Dermatol, 36: 101-103, 1997.
51. Loo Wj, Kirtschig G, Wojnarowska F: Minocycline as a therapeutic option in bullous pemphigoid, Clin Exp Dermatol, 26: 376-379, 2001.
52. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D: Nicotinamide and tetracycline therapy of bullous pemphigoid, Arch Dermatol, 130: 753-758, 1994.
53. Westerhof W: Treatmant of bullous pemphigoid with topical clobetasol propionate, J Am Acad Dermatol, 20: 458-461, 1989.
54. Paquet P, Richelle M, Lapiere CM: Bullous pemphigoid treated by topical corticosteroids, Acta Derm Venereol, 71: 534-535, 1991.
55. Muramatsu T, Iida T, Shirai T: Pemphigoid and pemhigus foliaceus successfully treated with topical corticosteroids, J Dermatol, 23: 683-688, 1996.
56. Spuls PI, Brakman M, Westerhof W, Bos JD: Treatment of generalized bullous pemphigoid with topical corticosteroids, Acta Derm Venerol, 75: 89, 1995.
57. Zimmermann R, Faure M, Claudy A: Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid, Ann Dermatol Venererol, 126: 13-16, 1999.
58. Liu Z, Shipley JM, Vu TH, et al: Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid, J Exp Med, 188: 475-482, 1998.
59. Staughton RC, August PJ: Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate, Br Med J, 2: 419-421, 1975.
60. Walsh P, Aeling JL, Huff L, Weston WL: Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids, J Am Acad Dermatol, 29: 501-503, 1993.
61. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI: Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations, J Am Acad Dermatol, 38: 318-321, 1998.
62. Dereure O, Bessis D, Guillot B, Guilhou JJ: Treatment of bullous pemphigoid by low dose methotrexate associated with short-term potent topical steroids: An open prospective study of 18 cases, Arch Dermatol, 138: 1255-1256, 2002.